|
HS Code |
835620 |
| Name | Tert - Butyl 3 - Amino - 3 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate |
| Molecular Formula | C10H20N2O3 |
| Molecular Weight | 216.277 g/mol |
| Appearance | Typically a solid (powder or crystalline) |
| Solubility In Water | Limited solubility, polar nature of -OH and -NH2 may enhance solubility slightly |
| Solubility In Organic Solvents | Soluble in polar organic solvents like methanol, ethanol, DMSO |
| Pka Value | Relevant functional groups: pKa of amino group around 9 - 11 |
| Stability | Stable under normal conditions, but sensitive to strong acids and bases |
As an accredited Tert-Butyl 3-Amino-3-(Hydroxymethyl)Pyrrolidine-1-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of Tert - Butyl 3 - Amino - 3 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate in sealed chemical - grade bag. |
| Shipping | Tert - Butyl 3 - Amino - 3 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate is shipped in accordance with chemical transportation regulations. Packed securely in appropriate containers to prevent leakage, ensuring safe transit to the destination. |
| Storage | Store “Tert - Butyl 3 - Amino - 3 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate” in a cool, dry place away from heat sources and open flames. Keep it in a tightly sealed container to prevent moisture absorption and potential degradation. Avoid storage near oxidizing agents and incompatible substances. Preferably store it in a dedicated chemical storage area following safety regulations. |
In the manufacture of aza-sugar-derived glycosidase inhibitors and pyrrolidine-based antiviral prodrugs, the introduction of the protected 3-amino-3-(hydroxymethyl)pyrrolidine core is typically executed after a selective Boc deblocking step. The process stream is charged with tert-butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate dissolved in anhydrous dichloromethane (moisture <0.05 % KF). Trifluoroacetic acid is metered in at 0–5 °C to achieve a 20–30 % v/v concentration while the jacket of a glass-lined reactor maintains the exotherm below 8 °C. After 2–3 h of aging, the deprotected amino alcohol is isolated as the bis-TFA salt by precipitation with methyl tert-butyl ether. Immediate coupling with an activated carboxylic acid partner—using EDC·HCl and HOBt in DMF at −10 °C to room temperature—yields the amide intermediate with >98.5 % conversion (HPLC, area %). Residual TFA in the final isolated intermediate is controlled to <100 ppm as mandated by ICH Q3C for Class 3 solvents. The entire sequence is run under GMP guidelines per ICH Q7 Section 7.3, with critical process parameters logged on a ±1 °C and ±2 rpm resolution. The resulting building block integrates into the pharmacophore of orally available thrombin inhibitors and hepatitis C NS3/4A protease inhibitors, where the hydroxymethyl group serves as a hydrogen-bond donor and the tertiary nitrogen modulates basicity. Batch release includes chiral HPLC (USP monograph general chapter <621>) and residual Pd analysis (ICP-MS, <5 ppm) if the substrate enters a catalytic hydrogenation sequence downstream.What Latent Amine Functionality Does the Boc-Carbamate Offer in One-Component Epoxy Adhesives?When formulated into a bisphenol A diglycidyl ether (DGEBA) system, tert-butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate remains inert under ambient storage but undergoes thermolytic deprotection above 120 °C, liberating the primary amine and a hydroxymethyl-bearing secondary amine that together crosslink the epoxy matrix. Dispersion is carried out in a planetary dual-blade mixer (P/V ratio 1:0.7) at 400–600 Pa·s initial viscosity, followed by a single pass through a three-roll mill with a gap set at <15 μm to eliminate agglomerates. Stoichiometry is adjusted to an active hydrogen-to-epoxy equivalent ratio of 0.85:1 to 1.05:1, which corresponds to a compound loading of 3–8 phr depending on the epoxy equivalent weight of the resin. Latency is quantified by oscillatory rheometry at 40 °C: a formulation containing 5 phr of the carbamate sustains a complex viscosity below 800 Pa·s for more than 3 500 min before gelation onset. Curing proceeds in a two-stage cycle—30 min at 120 °C followed by 60 min at 150 °C—in a forced-convection oven with a thermal uniformity of ±1.5 °C. The network structure benefits from the hydroxymethyl pendant group, which increases free volume and reduces internal stress without sacrificing crosslink density. Adhesion to degreased aluminium (2024-T3, grit-blasted profile 2–5 μm Ra) is measured per ISO 4587:2003. A representative property gradient at varying addition levels is collated in the table below.
When Incorporated into Thermally Switchable Polyurethane SealantsThermally latent catalysts derived from tert-butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate function by releasing free amino alcohol upon pyrolysis of the carbamate group at 145–165 °C, which then accelerates the polyaddition of polyether polyols and methylene diphenyl diisocyanate. The compound is pre-dissolved in the polyol fraction at 0.2–0.5 wt% relative to total prepolymer mass and dehydrated under vacuum at 90 °C and <10 mbar for 2 h until the water content drops below 0.02 %. After isocyanate addition, the mixture is degassed in a planetary centrifugal mixer at 2 000 rpm and dispensed into aluminium cartridges. Pot life at 25 °C extends to 6–8 h, compared to <45 min for conventionally catalysed systems, enabling single-component packaging that cures fully during a 20-min exposure to 160 °C in an infrared tunnel oven. Mechanical properties are evaluated according to ASTM D412 (die C): tensile strength reaches 4.2 MPa with elongation at break of 450 %. The cured sealant meets GB 33372-2020 VOC limits for construction sealants (TVOC <50 g/L). Primary application targets include thermally activated seam sealing in white-goods manufacturing where post-paint bake cycles provide the activation energy. A hard-stop operational boundary exists: exposure to relative humidity above 70 % during cartridge storage will hydrolyse the Boc group within 4 weeks and cause irreversible viscosity build-up, necessitating foil-laminated packaging and the inclusion of a desiccant bag.Incorporation of a constrained pyrrolidine scaffold into peptide backbones alters proteolytic stability. The compound, following quantitative TFA deprotection and kinetic resolution if required, is subjected to a two-step sequence: the secondary amine is reprotected with Fmoc-OSu in aqueous dioxane at pH 8.5, and the primary hydroxymethyl group is oxidised under TEMPO-NaOCl biphasic conditions (dichloromethane/water, 0 °C) to yield the corresponding β2-amino acid in 85 % yield after flash chromatography. This Fmoc-protected β-amino acid is loaded onto a 2-chlorotrityl chloride resin (loading 0.8 mmol/g) via the carboxylate, using 2.5 equivalents of the monomer and DIPEA in dichloromethane for 4 h. Subsequent solid-phase peptide synthesis proceeds under standard Fmoc-tBu protocols with HCTU activation on an automated microwave peptide synthesizer (CEM Liberty Blue) at 50 °C. Coupling efficiencies monitored by bromophenol blue test remain above 99.2 % per step. The resulting peptidomimetic sequences, bearing the 3-amino-pyrrolidine-3-carboxylic acid skeleton, exhibit a half-life greater than 24 h in human plasma (incubated at 37 °C), compared to <2 h for the corresponding linear peptide. Research-use-only peptides synthesised via this route fall under biosafety level 1 handling; no GMP certification is mandated, but the laboratory operation references USP <795> for non-sterile compounding quality standards. The methodology serves early-stage drug discovery programmes evaluating orally stable hormone mimetics and enzyme inhibitors.Derivatisation of spherical silica gel (particle size 5 μm, pore size 100 Å, specific surface area 300 m²/g) with tert-butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate provides a brush-type chiral stationary phase for normal-phase and polar-organic HPLC. The silica is first treated with 3-glycidoxypropyltrimethoxysilane in refluxing toluene ( 110 °C, 24 h) to yield an epoxy-functionalised surface with a bonding density of 2.8–3.2 μmol/m². The epoxy-modified silica is then suspended in a 0.2 M solution of the protected amino alcohol in N,N-dimethylformamide containing catalytic tetrabutylammonium bromide and heated to 80 °C for 48 h. Excess hydroxyl groups are end-capped with hexamethyldisilazane. Elemental analysis indicates a carbon loading increase of 4.6–5.1 %, corresponding to a ligand coverage of approximately 600 μmol/g. After packing into a 250 × 4.6 mm stainless steel column under 400 bar using a high-pressure slurry packer, the Boc group is removed in situ by flushing with 0.1 M methanolic HCl, exposing the zwitterionic amino alcohol binding site. The column resolves racemic naproxen (selectivity α 1.14, resolution Rs 1.9) and a range of profen drug substances under a mobile phase of n-hexane/2-propanol/trifluoroacetic acid (80:20:0.1 v/v/v) at 1.0 mL/min. System suitability tests follow USP <621> and ICH Q2(R1) for chromatography. The stationary phase demonstrates stable performance for over 2 000 injections with <5 % drift in retention factor, provided that the organic modifier content in the eluent does not drop below 15 % to avoid irreversible collapse of the bonded layer.
|
Competitive Tert-Butyl 3-Amino-3-(Hydroxymethyl)Pyrrolidine-1-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Specification | Test Method |
|---|---|---|
| Assay (anhydrous basis) | ≥ 95.0% | HPLC (RP-C18, 210 nm, ACN/H₂O 0.1% TFA gradient) |
| Appearance | White to off-white solid or viscous oil | Visual inspection, ambient light |
| Identity | ¹H NMR and ¹³C NMR consistent with structure | Bruker 400 MHz; CDCl₃ solvent, reference TMS |
| Water content (Karl Fischer) | ≤ 1.0% w/w | ISO 760:1978 |
| Chiral purity (if single enantiomer specified) | ≥ 98.0% ee | Chiral HPLC (Chiralpak AD-H, hexane/2-propanol) |
| Storage condition | Store at –20 ± 5 °C under inert gas | IATA QC guidelines for temperature-sensitive intermediates |
| Property | tert-Butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate | tert-Butyl 3-aminopyrrolidine-1-carboxylate | 3-Amino-3-(hydroxymethyl)pyrrolidine (unprotected) |
|---|---|---|---|
| Molecular weight | 216.28 g·mol⁻¹ | 186.25 g·mol⁻¹ | 116.16 g·mol⁻¹ |
| Thermal decomposition onset (DSC) | 88 °C | 96 °C | 144 °C (as hydrochloride salt) |
| Water solubility (log P, predicted) | –0.23 | 0.15 | –0.85 |
| Selectivity in amidation (N vs. O) | >99:1 (N-acylation) | N/A (no OH) | ~3:1 (O:N competition) |
| hERG liability of derived amides (clogP <2 counterion) | Lower risk; polar surface area >80 Ų | Moderate; PSA ~ 55 Ų | Variable; must salt-form for reduced lipophilicity |
| Typical catalog purity | ≥95% (HPLC) | ≥97% (GC or HPLC) | ≥93% (HPLC, hygroscopic) |